Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications

May 6, 2024

https://www.prnewswire.com/news-releases/chiesi-and-gossamer-bio-announce-transformative-global-collaboration-to-develop-and-commercialize-seralutinib-in-pulmonary-arterial-hypertension-and-other-respiratory-indications-302136742.html

SAN DIEGO and PARMA, Italy, May 6, 2024 /PRNewswire/ — Chiesi Farmaceutici S.p.A (“Chiesi Group”), an international, research-focused biopharmaceutical group, and Gossamer Bio, Inc. (“Gossamer”) (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, today announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.